| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
JTK-109 targets the hepatitis C virus NS5B RNA-dependent RNA polymerase, an essential enzyme for HCV genome replication. It binds to the thumb I (T1) allosteric site of NS5B, a non-nucleoside binding site distinct from the active site. By binding to this allosteric site, JTK-109 induces conformational changes that inhibit polymerase activity, preventing viral RNA synthesis. The compound inhibits G1b and G3a subgenomic replicons and recombinant enzymes.
|
|---|---|
| ln Vitro |
In vitro, JTK-109 demonstrates potent NS5B inhibitory activity with an IC₅₀ value of 0.017 μM. It shows antiviral activity against HCV in Huh-5-2 cells with an EC₅₀ of 0.32 μM. The compound has a CC₅₀ of >20 μM in Huh-5-2 cells and 25 μM by MTT assay. It inhibits G1b and G3a subgenomic replicons. The compound is a non-nucleoside inhibitor targeting the T1 allosteric site.
|
| ln Vivo |
JTK-109 has been investigated for the treatment of hepatitis C virus (HCV) infection. As a potent NS5B inhibitor, it represents a promising approach to HCV therapy. The compound's activity against multiple HCV genotypes (G1b and G3a) suggests broad-spectrum potential. Further clinical development would be required to establish its full therapeutic potential in HCV patients.
|
| Enzyme Assay |
NS5B polymerase inhibition assays are performed using purified HCV NS5B enzyme and appropriate RNA templates. Enzyme activity is measured by incorporation of radiolabeled nucleotides into newly synthesized RNA. JTK-109 is tested at various concentrations, and IC₅₀ values are calculated. Binding affinity for the T1 allosteric site is determined using surface plasmon resonance or isothermal titration calorimetry.
|
| Cell Assay |
In vitro antiviral assays are performed using Huh-5-2 cells harboring HCV subgenomic replicons. Cells are treated with JTK-109 at various concentrations. Antiviral activity is assessed by measuring replicon RNA levels using quantitative RT-PCR or luciferase reporter assays. Cytotoxicity is assessed by MTT assay. CC₅₀ and EC₅₀ values are calculated from dose-response curves. The compound is dissolved in DMSO for stock solutions.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of HCV infection, including human hepatocyte chimeric mouse models. JTK-109 is administered orally or intraperitoneally. Viral load is measured in serum by RT-qPCR. Liver tissues are collected for histopathological analysis and viral RNA quantification. Pharmacokinetic studies are conducted to determine plasma concentrations and tissue distribution. The compound's oral bioavailability and half-life are characterized.
|
| ADME/Pharmacokinetics |
JTK-109 has a molecular formula of C₃₇H₃₃ClFN₃O₄ with CAS number 480462-62-2. It is a benzimidazole-derived non-nucleoside inhibitor. The compound has an IC₅₀ of 0.017 μM against NS5B. Specific pharmacokinetic parameters (half-life, bioavailability, Cmax) are documented in the literature. Storage should be under recommended conditions as specified in product documentation. The compound is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for JTK-109 are documented in preclinical studies. In cell-based assays, the compound shows a CC₅₀ of >20 μM in Huh-5-2 cells and 25 μM by MTT assay, indicating a reasonable selectivity index. Standard laboratory safety precautions should be followed when handling this compound. It is intended for research use only and not for human therapeutic applications. The compound should be handled in a well-ventilated area with appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
JTK-109 is a benzimidazole-derived non-nucleoside inhibitor of HCV NS5B RNA-dependent RNA polymerase that binds to the thumb I (T1) allosteric site. It has potent NS5B inhibitory activity with an IC₅₀ of 0.017 μM and shows antiviral activity against HCV in cell-based replicon assays. The compound inhibits G1b and G3a subgenomic replicons, suggesting broad-spectrum activity against multiple HCV genotypes. It is commercially available for research purposes only and represents a valuable tool for studying HCV replication and developing new antiviral therapies.
|
| Molecular Formula |
C37H33CLFN3O4
|
|---|---|
| Molecular Weight |
638.13
|
| CAS # |
480462-62-2
|
| Related CAS # |
480462-62-2; 501371-90-0 (HCl);
|
| PubChem CID |
11686018
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
46
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
0
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5671 mL | 7.8354 mL | 15.6708 mL | |
| 5 mM | 0.3134 mL | 1.5671 mL | 3.1342 mL | |
| 10 mM | 0.1567 mL | 0.7835 mL | 1.5671 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
